RESUMEN
Background: Recent advances in the treatment of inflammatory bowel disease include antitumor necrosis factor antibodies and the Janus kinase inhibitor tofacitinib, approved for ulcerative colitis. Janus kinase recruits signal transducers and activators of transcriptions (STAT), which are promising targets in inflammatory bowel diseases. However few inhibitors have been evaluated, and their selectivity with respect to STAT1 and STAT3 remains controversial. Here, we investigated the therapeutic potential of a selective inhibitor vs. a non-selective, closely related compound, in a dextran sulfate sodium (DSS) murine colitis model. Methods: Thirty Swiss/CD-1 male mice were used in this study. They were divided into a healthy control group, a colitis-DSS control group, a compound (cpd) 23-treated group, a cpd 46-treated group and an icariin-treated group. For the coadministration experiment with rutin, the cpd 46-treated group and the icariin-treated group were replaced by the oral rutin-treated group and the coadministration rutin/cpd 23-treated group. The effect of the tested inhibitors was also assessed by quantification of proinflammatory markers. Results: The selective inhibitor had a significantly greater effect than the dual inhibitor on the disease activity index. We also noticed in curative treatment a significant decrease in the most abundant proinflammatory biomarker present in neutrophilic granulocytes, myeloperoxidase and on proinflammatory cytokines, including tumor necrosis factor-α, interferon-γ, interleukins -6 and -23, with a mild synergy with rutin, the glycoside of quercetin. Conclusion: The current study shows how STAT3 selective inhibitors can exert a significant therapeutic effect in the treatment of experimental DSS-colitis.
RESUMEN
Inflammatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory diseases of the gastrointestinal tract and are characterized by chronic recurrent ulceration of the bowels. Colon-targeted drug delivery systems (DDS) have received significant attention for their potential to treat IBD by improving the inflamed tissue selectivity. Herein, antiMUC5AC-decorated drug loaded nanoparticles (NP) are suggested for active epithelial targeting and selective adhesion to the inflamed tissue in experimental colitis. NPs conjugated with antiMUC5AC (anti-MUC5) were tested for their degree of bioadhesion with HT29-MTX cells by comparison with non-targeted BSA-NP conjugates. In vivo, the selectivity of bioadhesion and the influence of ligand density in bioadhesion efficiency as well as the therapeutic benefit for glucocorticoid loaded anti-MUC5-NP were studied in a murine colitis model. Quantitative adhesion analyses showed that anti-MUC5-conjugated NP exhibited a much higher binding and selectivity to inflamed tissue compared to PNA-, IgG1- and BSA-NP conjugates used as controls. This bioadhesion efficiency was found to be dependent on the ligand density, present at the NP surface. The binding specificity between anti-MUC5 ligand and inflamed tissues was confirmed by fluorescence imaging. Both anti-MUC5-NP and all other glucocorticoid containing formulations led to a significant mitigation of the experimental colitis, as became evident from the substantial reduction of myeloperoxidase activity and pro-inflammatory cytokine concentrations (TNF-α, IL-1ß). Targeted NP by using anti-MUC5 appears to be a very promising tool in future treatment of various types of local disorders affecting the gastro-intestinal tract but not limited to colitis.
Asunto(s)
Colitis , Nanopartículas , Ratones , Animales , Glucocorticoides/uso terapéutico , Ligandos , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Nanopartículas/química , Resultado del Tratamiento , Colon/diagnóstico por imagen , Colon/metabolismoRESUMEN
A major limitation in the current topical treatment strategies for inflammatory skin disorders is the inability to selectively target the inflamed site with minimal exposure of healthy skin. Atopic dermatitis is one of the most prevalent types of dermatitis. The use of polymeric nanoparticles for targeting inflamed skin has been recently proposed, and therefore the aim of this proof-of-concept clinical study was to investigate the skin penetration and deposition of polymeric biodegradable nanoparticles in the atopic dermatitis lesions and compare the data obtained to the deposition of the particles into the healthy skin or lesion-free skin of the atopic dermatitis patients. For that, fluorescent PLGA nanoparticles in sizes of approximately 100 nm were prepared and applied to the skin of healthy volunteers and the lesional and non-lesional skin of atopic dermatitis patients. Skin biopsies were examined using confocal laser scanning microscopy to track the skin deposition and depth of penetration of the particles. Immunohistochemistry was performed to investigate the alteration in tight-junction protein distribution in the different types of skin. Results have shown that nanoparticles were found to have higher deposition into the atopic dermatitis lesions with minimal accumulation in healthy or non-lesional skin. This has been primarily correlated with the impaired barrier properties of atopic dermatitis lesions with the reduced production of Claudin-1. It was concluded that polymeric nanoparticles offer a potential tool for selective drug delivery to inflamed skin with minimal exposure risk to healthy skin.
RESUMEN
Lipoproteins are natural nanostructures responsible for the transport of cholesterol and other lipids in the blood. They are characterized by having a lipophilic core surrounded by an amphiphilic shell composed of phospholipids, cholesterol and one or more apolipoproteins. Being endogenous carriers makes them suitable for drug delivery purposes. Here, we investigate the effect of lipoproteins' intricate composition on the entrapment efficiency of a model drug "Cyclosporine A" into the different types of lipoproteins, namely, HDL, LDL and VLDL. It was observed that the protein content of the lipoproteins had the highest effect on the entrapment of the drug with a correlation coefficient of 0.80, 0.81 and 0.96 for HDL, LDL and VLDL respectively. This was even confirmed by the effect of plasma on the association rate of lipoproteins and the drug. The second effective factor is the cholesterol concentration, while triglycerides and phospholipids had a negligible effect.
RESUMEN
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Although a deeper understanding of the underlying mechanisms of IBD has led to new therapeutic approaches, treatment options are still limited. Severe adverse events in conventional drug therapy and poor drug targeting are the main cause of early therapy failure. Nanoparticle-based targeting approaches can selectively deliver drugs to the site of inflammation and reduce the risk of side effects by decreasing systemic availability. Here, we developed a nanoparticulate platform for the delivery of the anti-TNF-α antibody adalimumab (ADA) by covalent crosslinking to the particle surface. ADA binding to nanoparticles improved the stability of ADA against proteolytic degradation in vitro and led to a significantly better therapeutic outcome in a murine colitis model. Moreover, immobilization of ADA reduced systemic exposure, which can lead to enhanced therapeutic safety. Thus, nanoparticle protein decoration constitutes a platform through which epithelial delivery of any biological of interest to the inflamed gut and hence a local treatment can be achieved.
RESUMEN
5-amino salicylic acid (5-ASA) is a standard therapy for the treatment of mild to moderate forms of inflammatory bowel diseases (IBD) whereas more severe forms involve the use of steroids and immunosuppressive drugs. Hyaluronic acid (HA) is a naturally occurring non-sulfated glycosaminoglycan that has shown epithelium protective effects in experimental colitis recently. In this study, both 5-ASA (30 mg/kg) and HA (15 mg/kg or 30 mg/kg) were administered rectally and investigated for their potential complementary therapeutic effects in moderate or severe murine colitis models. Intrarectal treatment of moderate and severe colitis with 5-ASA alone or HA alone at a dose of 30 mg/kg led to a significant decrease in clinical activity and histology scores, myeloperoxidase activity (MPO), TNF-α, IL-6 and IL-1ß in colitis mice compared to untreated animals. The combination of HA (30 mg/kg) and 5-ASA in severe colitis led to a significant improvement of colitis compared to 5-ASA alone. Combined rectal therapy with HA and 5-ASA could be a treatment alternative for severe cases of IBD as it was the only treatment tested that was not significantly different from the healthy control group. This study further underlines the benefit of searching for yet unexplored drug combinations that show therapeutic potential in IBD without the need of designing completely new drug entities.
RESUMEN
Findings from recent studies revealed a significant anti-inflammatory effect of polysaccharide-based excipients when formulated with classical drugs in experimental inflammatory bowel disease models. In this study, acacia and guar gum were investigated beyond their typical functionality for a possible additive anti-inflammatory effect when administered with 5-amino salicylic acid (5ASA) in murine experimental colitis. Anti-inflammatory effects of acacia and guar gum-based aqueous suspensions of 5ASA were evaluated in a murine experimental colitis. Acacia or guar gum (30 or 300 mg/kg) were administered via rectal administration alone or in combination with 5ASA (30 mg/kg). Disease activity, myeloperoxidase activity (MPO) and intratissue concentrations of various cytokines were assessed. Both acacia and guar gum separately showed significant effects in reducing the inflammatory markers in murine colitis model in vivo. When combined with the anti-inflammatory drug 5ASA, acacia showed a stronger therapeutic effect than guar gum, especially at the higher dose of acacia (300 mg/kg) which significantly reduced the inflammation in vivo compared to 5ASA alone (MPO, 5ASA: 5743 ± 1334, 5ASA + 30 mg/kg acacia: 3762 ± 2342; 5ASA + 30 mg/kg guar gum: 7373 ± 2115, 5ASA + 300 mg/kg acacia: 3131 ± 1012, 5ASA + 300 mg/kg guar gum: 6358 ± 2379; all U/g tissue). Acacia and guar gum separately showed significant anti-inflammatory effects in murine colitis, and furthermore, high dose acacia led to an additional therapeutic benefit when co-administered with 5ASA. These results indicate that further investigations are surely warranted in the search of better colitis therapy.
RESUMEN
Lipoproteins are biodegradable and biocompatible natural carriers that can be utilized for the transport of hydrophobic drugs, such as cyclosporin A (CycloA), a calcineurin inhibitor utilized for the inflammatory bowel disease, such as ulcerative colitis. A major limitation in the drug treatment of inflammatory bowel disease is the inability to deliver the drug selectively toward the inflamed tissues. Nanotechnology-based drug delivery systems have led to an amelioration of the therapeutic selectivity, but still the majority of the entrapped drug is eliminated without exercising a therapeutic effect. The present study aimed to prepare three lipoprotein formulations (HDL-, LDL-, and VLDL-based) loaded with cyclosporin A for the treatment of colitis in a murine model. After an intravenous injection of a drug dose of 2 mg/kg, clinical activity (colon weight/length ratio) and therapeutic effects (evaluated by the inflammatory markers MPO and TNF-α) were compared with those of the untreated colitis control group. All CycloA-containing lipoproteins reduced clinical activity, with a significant decrease in the case of LDL-CycloA formulation, which also led to the higher therapeutic effect.
Asunto(s)
Colitis Ulcerosa , Colitis , Animales , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Colitis Ulcerosa/tratamiento farmacológico , Colon , Ciclosporina , Lípidos , RatonesRESUMEN
Inflammatory bowel disease (IBD) refers to progressive inflammatory disorders that impair the gastrointestinal tract's structure and function. Given their selective accumulation in inflamed tissues, nanoparticles are promising drug delivery systems for IBD treatment. The hypothesis here was that drug-free nanoscaled cationic ammonio methacrylate copolymers (AMCNP) may have a beneficial therapeutic effect in murine TNBS-induced colitis. Type A and B AMCNP (RLNP and RSNP, respectively) were prepared and characterized in vitro, and were rectally administered in two concentrations (5 and 25 mg ml-1) for the treatment of two grades of murine experimental colitis. The impact of the nanoparticles upon the inflammatory markers, circulating LPS, intestinal permeability and colonic leukocyte populations was examined. Both RLNP and RSNP led to a significant mitigation of mild to moderate experimental colitis, as evident from the substantial reduction of myeloperoxidase (MPO) and alkaline phosphatase (AP) activities (more than two-fold, P < 0.05) and various pro-inflammatory cytokine concentrations (TNF-α, IL-1ß, IL-6, IL-12). The best therapeutic efficiency was observed when the particles were used at 5 mg ml-1, while the more cationic RLNP performed superior. When used against a severe grade of colitis, RLNP (5 mg ml-1) resulted in a significant decrease of tissue MPO and TNF-α. It was found that treatment with AMCNP resulted in significant intestinal immune cell depletion, intestinal barrier function improvement, and 1.5-2.5 times reduction of the systemic endotoxin concentration. These findings highlighted the fact that nanoscaling endows the cationic amphiphilic AMCs unique therapeutic properties, which help mitigate murine experimental colitis in the absence of any drug load. The results also provided a glimpse of possible underlying mechanisms through which nanoscaled AMCs might have exerted their therapeutic effect within this context.
Asunto(s)
Resinas Acrílicas/química , Resinas Acrílicas/uso terapéutico , Colitis/tratamiento farmacológico , Nanosferas/química , Nanosferas/uso terapéutico , Resinas Acrílicas/administración & dosificación , Resinas Acrílicas/farmacocinética , Administración Rectal , Animales , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Colon/efectos de los fármacos , Colon/inmunología , Colon/metabolismo , Mucosa Intestinal/efectos de los fármacos , Leucocitos/efectos de los fármacos , Leucocitos/inmunología , Lipopolisacáridos/sangre , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Ratones , Nanosferas/administración & dosificación , PermeabilidadRESUMEN
Epithelial administration of low molecular weight heparin (LMWH) has proven its therapeutic efficiency in ulcerative colitis (UC) but still lacks of a sufficiently selective drug delivery system. Polymeric nanoparticles were used here not only to protect LMWH from intestinal degradation but also to provide targeted delivery to inflamed tissue in experimental colitis mice. LMWH was associated with polymethacrylate nanoparticles (NP) type A (PEMT-A) or type B (PEMT-B) of a size: 150 nm resulting in a maximum drug loading: 0.1 mg/mg. In a lipopolysaccharide-stimulated macrophages both, free LMWH and LMWH-NP have significantly reduced the cytokines secretion independently from cellular uptake. The in-vivo therapeutic efficiency was dose dependent as at low doses (100 IU/kg) only minor differences between free LMWH and LMWH-NP were found and the superiority of LMWH-NP became prominent with dose increase (500 IU/kg). Administration of LMWH-NP at 500 IU/kg has markedly improved the clinical activity as compared to LMWH while similarly pathophysiological indicators revealed increased therapeutic outcome in presence of NP compared to LMWH alone: Myeloperoxidase (Colitis control: 10 480 ± 5335, LMWH-PEMT-A NP: 1507 ± 2165, LMWH-PEMT-B NP: 382 ± 143, LMWH: 8549 ± 5021 units/g) and tumor necrosis factor: (Colitis control: 1636 ± 544, LMWH-PEMT-A NP: 511 ± 506, LMWH-PEMT-B NP: 435 ± 473, LMWH: 1110 ± 309 pg/g). Associating LMWH with NP is improving the anti-inflammatory efficiency of LMWH in-vivo by its protection against degradation in luminal environment and selective drug delivery. Such a combination holds promise for a highly specific therapy by its double selectivity towards the inflamed intestinal tissue. LMWH-PEMT NP have significantly improved the clinical activity in-vivo in comparison to free LMWH.
Asunto(s)
Colitis Ulcerosa , Nanopartículas , Animales , Colitis , Sistemas de Liberación de Medicamentos , Heparina de Bajo-Peso-Molecular , RatonesRESUMEN
The oral bioavailability of drugs is often limited due to the presence of the P-glycoprotein, an efflux pump strongly expressed on the luminal side of the intestinal barrier. In an attempt to circumvent drug efflux, strategies consisting in the coadministration of drugs with surface-active agents have been found to be promising. In this context, the role of saponins on the intestinal permeability of a P-glycoprotein substrate was investigated. The P-glycoprotein inhibition activity of three triterpenoid saponins extracted from several plants of the Caryophyllaceae family was evaluated using an intestinal barrier model comprised of Caco-2 cell lines. The results showed a strong effect of two saponins on P-glycoprotein-mediated transport. At a concentration of 15 µM, the efflux ratio was close to 1 for both saponins, thus suggesting a total inhibition of the efflux pump in contrast to verapamil HCl, a conventional P-glycoprotein inhibitor. In addition, measurements of the transepithelial electrical resistance revealed that the integrity of the monolayers was not altered at such concentrations, thereby reducing potential adverse effects. The presence of acetylated sugars in the saponin structure could possibly facilitate interactions with the efflux pump by an ATP-dependent mechanism or by fluidization of cell membranes.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Caryophyllaceae/química , Saponinas/farmacología , Triterpenos/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Células CACO-2 , Humanos , Mucosa Intestinal/metabolismo , Permeabilidad/efectos de los fármacos , Saponinas/aislamiento & purificación , Triterpenos/aislamiento & purificaciónRESUMEN
A major limitation in the current topical treatment of inflammatory skin diseases is the inability to selectively deliver the drug to the inflammation site. Recently, smart drug delivery systems such as nanocarriers are being investigated to enhance the selective deposition of anti-inflammatory drugs in inflamed areas of the skin to achieve higher therapeutic efficacy with minimal side effects. Of such systems, polymeric nanoparticles are considered very efficient carriers for the topical drug delivery. In the current work, poly(l-lactide-co-glycolide) nanoparticles of nominal sizes of 70nm (NP70) and 300nm (NP300) were studied for their intra-epidermal distribution in murine and pig atopic dermatitis models over time against the respective healthy controls. Confocal laser scanning microscopical examination of skin biopsies was utilized for the qualitative and semi-quantitative analyses of nanoparticles skin deposition and penetration depth. While no skin penetration was found for any of the particles in healthy skin, the accumulation of NP70 was significantly higher than NP300 in inflamed skin (15-fold in mice, 5-fold in pigs). Penetration depth of NP70 decreased over time in mice from 55±3µm to 20±2µm and similar tendencies were observed for the other formulations. In inflamed pig skin, a similar trend was found for the penetration depth (NP70: 46±12µm versus NP300: 23±3µm); however, the NP amount remained constant for the whole analyzed period. Their ability to penetrate specifically into inflamed skin combined with minimal effects on healthy skin underlines small polymeric nanoparticles' potential as selective drug carriers in future treatment of chronic inflammatory skin diseases such as atopic dermatitis.
Asunto(s)
Dermatitis Atópica/metabolismo , Modelos Animales de Enfermedad , Nanopartículas/química , Nanopartículas/metabolismo , Tamaño de la Partícula , Absorción Cutánea/efectos de los fármacos , Administración Cutánea , Animales , Dermatitis Atópica/tratamiento farmacológico , Femenino , Masculino , Ratones , Nanopartículas/administración & dosificación , Técnicas de Cultivo de Órganos , Absorción Cutánea/fisiología , PorcinosRESUMEN
A major limitation in the drug treatment of inflammatory bowel disease is the inability to deliver the drug selectively towards the inflamed tissues. Nanotechnology-based drug delivery systems have led to an amelioration of the therapeutic selectivity but still the majority of the entrapped drug is eliminated without exercising a therapeutic effect. Here, lectin-decorated drug loaded nanoparticles (NP) are suggested for active targeting and selective adhesion to the inflamed tissue in experimental colitis. Peanut (PNA) and wheat germ (WGA) lectins were covalently bound to the surface of NP and were tested for their stability and degree of bioadhesion in cell culture. In-vivo, the selectivity of bioadhesion and distribution of NP throughout the intestinal tract as well as the therapeutic benefit for glucocorticoid loaded lectin-NP was studied in murine colitis models. Quantitative adhesion analyses showed that lectin-conjugated NP exhibited a much higher binding and selectivity to inflamed tissue compared to plain NP (PNA conjugates: 52.2±5.6%; WGA conjugates: 22.0±0.8%; plain NP: 18.6±9.8%). Lectin-associated NP revealed a further increase in the selectivity of bioadhesion towards inflamed tissues which partially translates into increased therapeutic efficiency. In terms of therapeutic efficiency, all glucocorticoid containing formulations revealed an enhanced therapeutic effect with lectin conjugates especially PNA-NP (myeloperoxidase: 55±37U/g; TNF-alpha: 3880±380U/g) compared to plain NP (myeloperoxidase: 145±98U/g; TNF-alpha: 6971±1157U/g). Targeted NP by using lectins, especially with PNA, as stable targeting moiety in the gastrointestinal tract appears to be a very promising tool in future treatment of inflammatory bowel disease.
Asunto(s)
Colitis/tratamiento farmacológico , Portadores de Fármacos/metabolismo , Sistemas de Liberación de Medicamentos , Glucocorticoides/administración & dosificación , Nanopartículas/metabolismo , Aglutinina de Mani/metabolismo , Aglutininas del Germen de Trigo/metabolismo , Animales , Sitios de Unión , Colitis/metabolismo , Colitis/patología , Portadores de Fármacos/química , Glucocorticoides/uso terapéutico , Intestino Grueso/efectos de los fármacos , Intestino Grueso/metabolismo , Intestino Grueso/patología , Masculino , Ratones , Nanopartículas/química , Aglutinina de Mani/química , Aglutininas del Germen de Trigo/químicaRESUMEN
The efflux transporter P-glycoprotein, expressed at high levels at the blood-brain barrier, exerts a profound effect on the disposition of various therapeutic compounds in the brain. A rapid and efficient modulation of this efflux transporter could enhance the distribution of its substrates and thereby improve central nervous system pharmacotherapies. This study explored the impact of the intravenous coadministration of two P-glycoprotein modulators, tariquidar and elacridar, on the pharmacokinetics and brain distribution of loperamide, a P-glycoprotein substrate probe, in rats. After 1 hour postdosing, tariquidar and elacridar, both at a dose of 1.0 mg/kg, increased loperamide levels in the brain by 2.3- and 3.5-fold, respectively. However, the concurrent administration of both P-glycoprotein modulators, each at a dose of 0.5 mg/kg, increased loperamide levels in the brain by 5.8-fold and resulted in the most pronounced opioid-induced clinical signs. This phenomenon may be the result of a combined noncompetitive modulation by tariquidar and elacridar. Besides, the simultaneous administration of elacridar and tariquidar did not significantly modify the pharmacokinetic parameters of loperamide. This observation potentially allows the concurrent use of low but therapeutic doses of P-gp modulators to achieve full inhibitory effects.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Acridinas/farmacología , Analgésicos/farmacocinética , Encéfalo/metabolismo , Loperamida/farmacocinética , Quinolinas/farmacología , Tetrahidroisoquinolinas/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Acridinas/administración & dosificación , Analgésicos/administración & dosificación , Analgésicos/sangre , Analgésicos/farmacología , Animales , Encéfalo/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Loperamida/administración & dosificación , Loperamida/sangre , Loperamida/farmacología , Masculino , Espectrometría de Masas , Quinolinas/administración & dosificación , Quinolinas/sangre , Ratas , Ratas Sprague-Dawley , Receptores Opioides mu/agonistas , Tetrahidroisoquinolinas/administración & dosificación , Tetrahidroisoquinolinas/sangre , Distribución TisularRESUMEN
Inflammatory bowel disease is a chronic relapsing inflammation of the gut with the two main forms being ulcerative colitis and Crohn's disease. Nanoparticulate drug carrier systems have been proven to enhance the therapeutic efficiency and to diminish adverse effects of the anti-inflammatory treatment due to their size dependent accumulation in the inflamed regions of the gut. The influence of surface properties on the accumulation selectivity and intensity of such nanoparticles is mainly unclear. Accordingly sized particles (~200 nm) were prepared by the emulsification solvent evaporation technique using different surfactants (polysorbate 20, sodium dodecyl sulphate, sodium cholate, cetyltrimethylammonium bromide, polyvinyl alcohol). In a murine colitis model the particles prepared with polysorbate 20 as surfactant led to a 34.8-fold higher particle content in the inflamed areas of the colon compared to the healthy gut and to a 4.5-fold increase of the particle content in the inflamed segments compared to particles prepared with sodium dodecyl sulphate. This effect translates also into a significantly higher mitigating effect when entrapping betamethasone into such nanoparticles. This study shows the importance of surface properties for the passive targeting approach in experimental colitis. The influence seems to be as important as the influence of the particle size.
Asunto(s)
Antiinflamatorios/administración & dosificación , Betametasona/administración & dosificación , Colitis/tratamiento farmacológico , Portadores de Fármacos/química , Nanopartículas/química , Tensoactivos/química , Animales , Antiinflamatorios/uso terapéutico , Betametasona/uso terapéutico , Línea Celular , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos BALB CRESUMEN
Dose limitations in therapy induced by adverse effects due to unselective drug availability are a common problem. One prominent example for this dilemma are inflammatory diseases of the gastrointestinal tract. The challenge for drug delivery systems in the therapy of these diseases is the delivery of the active ingredient to the site of inflammation. Colloidal carriers allow to improve delivery of drugs to the site of action and appear promising to overcome this general therapeutic drawback. Here we focus on nanocarrier-based drug delivery strategies for the treatment of common inflammatory disorders like inflammatory bowel disease and gastric ulcer.
Asunto(s)
Portadores de Fármacos/administración & dosificación , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Nanopartículas/administración & dosificación , Úlcera Gástrica/tratamiento farmacológico , Animales , Tracto Gastrointestinal/metabolismo , Humanos , Inflamación/tratamiento farmacológicoRESUMEN
Polymeric nanoparticles (NPs) are interesting drug carriers for dermal application and drug targeting to certain skin structures. NP interactions with diseased skin and the associated benefits and risks have been hardly explored. Today, we study the behavior of polymeric NPs for selective drug delivery to inflamed skin. Neutral, cationic, and anionic NPs of nominal diameters around 100 nm were administered to an experimental dithranol-induced dermatitis inflammation model in mice ears. The results showed that the surface charge had an important influence on the penetration and accumulation tendency in the inflamed skin compared with the neutral and cationic (2.8 ± 0.3%, 2.1 ± 0.2%, and 1.9 ± 0.3% for anionic, neutral, and cationic particles, respectively). Confocal laser scanning microscopy showed that all particles were accumulated in the inflamed pilosebaceous units. Betamethasone-loaded NPs showed that both charged particles were therapeutically more efficient than the neutral ones. Treatment with anionic and cationic particles led to the reduction of the inflammatory enzyme alkaline phosphatase activity by 50.7 ± 2% and 57.7 ± 5%, respectively, in comparison with the inflamed control. Noncharged particles had a lower therapeutic impact where the activity was only reduced by a factor of 75%. Histological sections examination had also confirmed these results. Therefore, it was concluded that the presence of charge could enhance skin-NPs adhesion and interaction leading to higher therapeutic effect on inflamed skin.
Asunto(s)
Dermatitis/metabolismo , Nanopartículas , Fosfatasa Alcalina/metabolismo , Animales , Ratones , Microscopía Confocal , Peroxidasa/metabolismo , Propiedades de SuperficieRESUMEN
Inflammatory reactions of the skin are a major therapeutic field; however, drug delivery is nowadays only related to the use of classical formulations like ointments and creams. Here, we report the behaviour of polymeric submicron particles (NP) for selective drug delivery to the inflamed skin. NPs of nominal diameters from 50 to 1000 nm were administered to an experimental dithranol-induced dermatitis inflammation model in mice ears. The results revealed that smaller particles had an around 3-fold stronger and deeper penetration tendency with a preferential accumulation in inflamed skin hair follicles and sebaceous glands (2.8 ± 0.6% and 2.3 ± 0.4% for NP100 and NP50 compared to 0.84 ± 0.04% and 0.92 ± 0.02% for the same sizes on healthy skin). Betamethasone loaded NP confirmed the size dependency by being therapeutically more efficient from histological examination and measurement of different inflammatory markers in the skin (myeloperoxidase activity of untreated control, 1.2 ± 0.4; NP1000, 1.0 ± 0.4; NP100, 0.5 ± 0.2, all U/mg). This approach holds a high potential for a selective therapy to the inflamed skin by increasing the local intradermal availability with simultaneous reduction in systemic adverse effects.
Asunto(s)
Antiinflamatorios/farmacología , Betametasona/farmacología , Dermatitis/tratamiento farmacológico , Sistemas de Liberación de Medicamentos , Administración Cutánea , Animales , Antiinflamatorios/administración & dosificación , Betametasona/administración & dosificación , Dermatitis/patología , Modelos Animales de Enfermedad , Folículo Piloso/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Nanopartículas , Tamaño de la Partícula , Glándulas Sebáceas/patología , Absorción CutáneaRESUMEN
Zinc-pectinate beads are interesting drug carriers for oral delivery. In order to investigate their in vitro and in vivo release behaviour, ionotropic gelation was used to entrap theophylline into calcium- or zinc-pectinate beads. Beads were investigated in vitro for their particle properties, especially the release kinetic in different media, and their in vivo pharmacokinetic parameters were tested in rats. Particle size varied between 1.8 and 2.8mm and encapsulation rates between 27 and 30% for Ca- and Zn-pectinate beads, respectively. While Ca-pectinate beads revealed a relative fast disintegration, drug release profiles from Zn-pectinate beads were very much release medium-dependent. Especially, in the presence of phosphate ions, the release from Zn-pectinate beads was blocked at 20% and 40% of the total drug load when tested in phosphate buffer or simulated colonic medium. In vivo Zn-pectinate beads (t(max): 12.0 ± 0.1h) led to a significant lag time for the theophylline absorption compared to Ca-pectinate (t(max): 6.0 ± 2.8h) or free theophylline (t(max): 2.5 ± 2.1h). This delayed release was attributed to the formation of a zinc phosphate coating in vitro and in vivo inducing the retention of theophylline release. Zn-pectinate beads exhibit interesting properties due to its potential as pulsatile delivery system induced by the in situ formation of Zn phosphate, while Ca-pectinate was found to be of limited suitability for controlled release of theophylline.
Asunto(s)
Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos/métodos , Excipientes/química , Pectinas/química , Administración Oral , Animales , Broncodilatadores/administración & dosificación , Broncodilatadores/análisis , Broncodilatadores/química , Broncodilatadores/farmacocinética , Cloruro de Calcio/química , Composición de Medicamentos/métodos , Geles/química , Pectinas/administración & dosificación , Ratas , Ratas Sprague-Dawley , Solubilidad , Suspensiones/química , Teofilina/administración & dosificación , Teofilina/análisis , Teofilina/química , Teofilina/farmacocinética , Agua/químicaRESUMEN
Lipid nanocapsules (LNC) have been suggested for a variety of pharmaceutical applications. Among them approaches for drug delivery to the skin appear particularly interesting. The current standard composition has been modified to better understand their properties by selecting a variety of different surfactants. LNC have been prepared using different non-ionic surfactants (Solutol(®) HS15: Polyoxyl 15 Hydroxystearate; Cremophor(®) EL: Polyoxyl 35 Castor Oil; Simulsol(®) 4000: Polyoxyl 40 Hydrogenated Castor Oil; Vitamin E TPGS(®): alpha-tocopheryl poly(ethylene glycol) succinate; Polysorbate 20 and 80) and analysed for their size, stability, drug release and toxicity on keratinocytes in cell culture. The feasibility of LNC using different surfactant was surprisingly easy and led to a variety of stable formulations that were selected for further investigations. Surfactants led to a variability of the release kinetics (t50% release varied from Polysorbate 20: 2.5h to Simulsol(®) 4000: 5.0h), however different formulations from the same surfactant did not differ significantly. In vitro toxicity of LNC was surfactant type dependent and a correlation between LNC and the pure respective surfactant was found. This toxicity was found to be mainly independent from the surface active properties. The surfactant type in LNC is easily interchangeable from formulation point of view. LNC appear to be appropriate as carrier for cutaneous delivery however toxicity can vary distinctly depending on the surfactant used for the preparation.